BLFS
Biolife Solutions Inc
NASDAQ · Life Sciences Tools & Services
$22.43
+0.41 (+1.86%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 85.97M | 97.28M | 1.23B | 1.26B | 1.01B |
| Net Income | -21,093,659 | -21,482,735 | 60.33M | 58.21M | 63.51M |
| EPS | — | — | — | — | — |
| Profit Margin | -24.5% | -23.3% | 4.9% | 4.6% | 6.3% |
| Rev Growth | -11.6% | -11.6% | +2.9% | +9.5% | +17.1% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 23.60M | 23.60M | 453.87M | 538.01M | 550.42M |
| Total Equity | 516.38M | 516.38M | 665.33M | 666.68M | 636.38M |
| D/E Ratio | 0.05 | 0.05 | 0.68 | 0.81 | 0.86 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -4,073,324 | -4,378,927 | 76.01M | 80.62M | 66.64M |
| Free Cash Flow | — | — | 34.19M | 44.34M | 36.90M |